Saravana Mohan Dhanasekaran

Saravana Mohan Dhanasekaran

Auto-generated profile, based on publicly available information

Saravana Mohan Dhanasekaran

Michigan Center for Translational Pathology

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2015 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MIMatthew K Iyer
Matthew K Iyer
YNYashar S Niknafs
Yashar S Niknafs
RMRohit Malik
Rohit Malik
USUdit Singhal
Udit Singhal
ASAnirban Sahu
Anirban Sahu
ACArul M Chinnaiyan
Arul M Chinnaiyan

20 May 2012 in Nature
Verified
Journal Article
Open access
PDF file
CGCatherine S. Grasso
Catherine S. Grasso
YWYi-Mi Wu
Yi-Mi Wu
DRDan R. Robinson
Dan R. Robinson
XCXuhong Cao
Xuhong Cao
SDSaravana M. Dhanasekaran
Saravana M. Dhanasekaran
STScott A. Tomlins
Scott A. Tomlins
Exome sequencing is used to investigate the role of mutations and copy number aberrations in metastatic castration-resistant prostate cancer, revealing recurrent mutations in multiple chromatin/histone modifying genes, as well as genes involved in androgen signalling. Great strides have been made in the treatment of localized prostate cancer, but the metastatic disease and its progression to castration-resistant prostate cancer (CRPC) are commonly lethal. This study uses whole-exome sequencing of 132 samples comprising tumour and matched germ line from 50 patients with heavily treated CRPC, and 11 untreated high-grade localized prostate cancers. Although the overall mutation rate is low, the authors find recurrent mutations in multiple chromatin/histone-modifying genes, as well as in the gene encoding the androgen receptor. They identify a diverse series of potentially driving mutations and copy-number alterations in both known and novel genes and pathways, including FOXA1. Characterization of the prostate cancer transcriptome and genome has identified chromosomal rearrangements and copy number gains and losses, including ETS gene family fusions, PTEN loss and androgen receptor (AR) amplification, which drive prostate cancer development and progression to lethal, metastatic castration-resistant prostate cancer (CRPC)1. However, less is known about the role of mutations2,3,4. Here we sequenced the exomes of 50 lethal, heavily pre-treated metastatic CRPCs obtained at rapid autopsy (including three different foci from the same patient) and 11 treatment-naive, high-grade localized prostate cancers. We identified low overall mutation rates even in heavily treated CRPCs (2.00 per megabase) and confirmed the monoclonal origin of lethal CRPC. Integrating exome copy number analysis identified disruptions of CHD1 that define a subtype of ETS gene family fusion-negative prostate cancer. Similarly, we demonstrate that ETS2, which is deleted in approximately one-third of CRPCs (commonly through TMPRSS2:ERG fusions), is also deregulated through mutation. Furthermore, we identified recurrent mutations in multiple chromatin- and histone-modifying genes, including MLL2 (mutated in 8.6% of prostate cancers), and demonstrate interaction of the MLL complex with the AR, which is required for AR-mediated signalling. We also identified novel recurrent mutations in the AR collaborating factor FOXA1, which is mutated in 5 of 147 (3.4%) prostate cancers (both untreated localized prostate cancer and CRPC), and showed that mutated FOXA1 represses androgen signalling and increases tumour growth. Proteins that physically interact with the AR, such as the ERG gene fusion product, FOXA1, MLL2, UTX (also known as KDM6A) and ASXL1 were found to be mutated in CRPC. In summary, we describe the mutational landscape of a heavily treated metastatic cancer, identify novel mechanisms of AR signalling deregulated in prostate cancer, and prioritize candidates for future study.

10 October 2002 in Nature
Verified
Journal Article
Closed access
PDF file
Sooryanarayana VaramballySooryanarayana Varambally
Sooryanarayana Varambally
SDSaravana M. Dhanasekaran
Saravana M. Dhanasekaran
MZMing Zhou
Ming Zhou
TBTerrence R. Barrette
Terrence R. Barrette
CKChandan Kumar-Sinha
Chandan Kumar-Sinha
ACArul M. Chinnaiyan
Arul M. Chinnaiyan

23 August 2001 in Nature
Verified
Journal Article
Open access
PDF file
SDSaravana M. Dhanasekaran
Saravana M. Dhanasekaran
TBTerrence R. Barrette
Terrence R. Barrette
DGDebashis Ghosh
Debashis Ghosh
RSRajal Shah
Rajal Shah
Sooryanarayana VaramballySooryanarayana Varambally
Sooryanarayana Varambally
ACArul M. Chinnaiyan
Arul M. Chinnaiyan
Prostate cancer is the most frequently diagnosed cancer in American men1,2. Screening for prostate-specific antigen (PSA) has led to earlier detection of prostate cancer3, but elevated serum PSA levels may be present in non-malignant conditions such as benign prostatic hyperlasia (BPH). Characterization of gene-expression profiles that molecularly distinguish prostatic neoplasms may identify genes involved in prostate carcinogenesis, elucidate clinical biomarkers, and lead to an improved classification of prostate cancer4,5,6. Using microarrays of complementary DNA, we examined gene-expression profiles of more than 50 normal and neoplastic prostate specimens and three common prostate-cancer cell lines. Signature expression profiles of normal adjacent prostate (NAP), BPH, localized prostate cancer, and metastatic, hormone-refractory prostate cancer were determined. Here we establish many associations between genes and prostate cancer. We assessed two of these genes—hepsin, a transmembrane serine protease, and pim-1, a serine/threonine kinase—at the protein level using tissue microarrays consisting of over 700 clinically stratified prostate-cancer specimens. Expression of hepsin and pim-1 proteins was significantly correlated with measures of clinical outcome. Thus, the integration of cDNA microarray, high-density tissue microarray, and linked clinical and pathology data is a powerful approach to molecular profiling of human cancer.

1 August 2011 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
JPJohn R Prensner
John R Prensner
MIMatthew K Iyer
Matthew K Iyer
OBO Alejandro Balbin
O Alejandro Balbin
SDSaravana M Dhanasekaran
Saravana M Dhanasekaran
QCQi Cao
Qi Cao
ACArul M Chinnaiyan
Arul M Chinnaiyan
New noncoding RNAs can be discovered by assembling transcripts from RNA-Seq data. Prensner et al. apply this approach across >100 prostate cancer samples to find noncoding RNAs that distinguish localized tumors from benign forms of the disease. Noncoding RNAs (ncRNAs) are emerging as key molecules in human cancer, with the potential to serve as novel markers of disease and to reveal uncharacterized aspects of tumor biology. Here we discover 121 unannotated prostate cancer–associated ncRNA transcripts (PCATs) by ab initio assembly of high-throughput sequencing of polyA+ RNA (RNA-Seq) from a cohort of 102 prostate tissues and cells lines. We characterized one ncRNA, PCAT-1, as a prostate-specific regulator of cell proliferation and show that it is a target of the Polycomb Repressive Complex 2 (PRC2). We further found that patterns of PCAT-1 and PRC2 expression stratified patient tissues into molecular subtypes distinguished by expression signatures of PCAT-1–repressed target genes. Taken together, our findings suggest that PCAT-1 is a transcriptional repressor implicated in a subset of prostate cancer patients. These findings establish the utility of RNA-Seq to identify disease-associated ncRNAs that may improve the stratification of cancer subtypes.

17 December 2006 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
STScott A Tomlins
Scott A Tomlins
RMRohit Mehra
Rohit Mehra
DRDaniel R Rhodes
Daniel R Rhodes
XCXuhong Cao
Xuhong Cao
LWLei Wang
Lei Wang
ACArul M Chinnaiyan
Arul M Chinnaiyan